Compare ALIT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | FULC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.4M | 467.8M |
| IPO Year | 2020 | 2019 |
| Metric | ALIT | FULC |
|---|---|---|
| Price | $0.75 | $3.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $3.75 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 25.6M | 2.4M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | ★ 21.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $2.83 |
| 52 Week High | $6.03 | $15.74 |
| Indicator | ALIT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 25.82 |
| Support Level | $0.67 | N/A |
| Resistance Level | $1.01 | $8.18 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | -0.02 | -0.34 |
| Stochastic Oscillator | 6.43 | 18.40 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.